Back to User profile » Dr Masahiro Seike
Papers published by Dr Masahiro Seike:
Difference in Respiratory Function Between GOLD Stage 1 and Preserved Ratio Impaired Spirometry as Assessed by Impulse Oscillometry and Spirometry
Shimizu A, Hino M, Kubota K, Yoshikawa A, Kamio K, Tanaka Y, Seike M
International Journal of Chronic Obstructive Pulmonary Disease 2026, 21:571172
Published Date: 23 January 2026
Early Intervention with Mepolizumab, Corticosteroids, and Intravenous Immunoglobulin for Dupilumab-Triggered Eosinophilic Granulomatosis with Polyangiitis: A Case Report
Kaburaki S, Tanaka T, Kamio K, Tanaka Y, Kasahara K, Seike M
Journal of Asthma and Allergy 2025, 18:559-565
Published Date: 13 April 2025
Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric Study
Iso H, Yomota M, Shirakura Y, Yoshinaga T, Kawai S, Narita K, Seike M, Hosomi Y
OncoTargets and Therapy 2025, 18:379-387
Published Date: 19 March 2025
Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series
Shimbu K, Hisakane K, Kadoma N, Nishima S, Atsumi K, Seike M, Hirose T
OncoTargets and Therapy 2024, 17:717-726
Published Date: 29 August 2024
Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
Iso H, Miyanaga A, Kadoma N, Shinbu K, Tozuka T, Murata A, Nishima S, Sato Y, Nakamichi S, Matsumoto M, Noro R, Terasaki Y, Kubota K, Seike M
OncoTargets and Therapy 2023, 16:465-470
Published Date: 23 June 2023
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
Misawa K, Nakamichi S, Iida H, Nagano A, Mikami E, Tozuka T, Matsumoto M, Miyanaga A, Noro R, Kubota K, Yamaguchi H, Seike M
OncoTargets and Therapy 2023, 16:65-69
Published Date: 24 January 2023
Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
Hayashi A, Nakamichi S, Nakayama Y, Nagano A, Mikami E, Takano N, Tozuka T, Matsumoto M, Miyanaga A, Noro R, Terasaki Y, Kubota K, Seike M, Gemma A
OncoTargets and Therapy 2022, 15:637-642
Published Date: 7 June 2022
Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
Kato Y, Kato Y, Minegishi Y, Suzuki T, Nakamichi S, Matsumoto M, Miyanaga A, Noro R, Kubota K, Terasaki Y, Seike M, Gemma A
OncoTargets and Therapy 2021, 14:5315-5319
Published Date: 23 November 2021
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
Sugano T, Seike M, Noro R, Kaburaki S, Tozuka T, Takahashi A, Takano N, Tanaka T, Kashiwada T, Takeuchi S, Minegishi Y, Saito Y, Kubota K, Terasaki Y, Gemma A
OncoTargets and Therapy 2018, 11:5879-5883
Published Date: 17 September 2018
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
Tozuka T, Seike M, Minegishi Y, Kitagawa S, Kato T, Takano N, Hisakane K, Takahashi S, Kobayashi K, Kashiwada T, Sugano T, Takeuchi S, Kunugi S, Noro R, Saito Y, Kubota K, Gemma A
OncoTargets and Therapy 2018, 11:5601-5605
Published Date: 7 September 2018